Citation APA
Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J. J., Casasnovas, O., Hamad, N., Zijlstra, J. J., Bakhshi, S., Bouabdallah, R., Choquet, S., Gurion, R., Hill, B., Jaeger, U., Sancho, J. M., Schuster, M., Thieblemont, C., De la Cruz, F., Egyed, M., Mishra, S., Offner, F., Vassilakopoulos, T., Warzocha, K., McCarthy, D., Ma, X., Corona, K., Saint-Martin, J.-R., Chang, H., Landesman, Y., Joshi, A., Wang, H., Shah, J., Shacham, S., Kauffman, M., Van Den Neste, E., & Canales, M. Á. M. (2020). Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. The Lancet Haematology, 7(7), e511-e522. doi:10.1016/S2352-3026(20)30120-4
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/309138